LAMP
The firm has multiple infectious disease tests in its pipeline and is currently in initial conversations with potential investors and partners.
The pharmaceutical firm said the decision was related to the cost associated with the molecular tests.
The molecular test is used to differentiate bacterial infections, viral infections, and noninfectious disease and to assess the risk that patients will develop severe illness.
Inflammatix Raises $57M in Series E Financing
The company said that it will use the money to support regulatory filings and commercialization of its 30-minute TriVerity Acute Infection and Sepsis Test.
The Paris-based startup plans to use €1.5 million in pre-seed funding to support R&D on a test kit and deliver preclinical data by early 2025.
Jan 31, 2024
Nov 28, 2023
Oct 11, 2023
Sep 14, 2023
Apr 27, 2023
Apr 21, 2023